# Phase II Study of CMS-D002 Capsule for Uterine Fibroids With Menorrhagia

> **NCT07402369** · PHASE2 · RECRUITING · sponsor: **Shenzhen Kangzhe Biotechnology Co., Ltd.** · enrollment: 120 (estimated)

## Conditions studied

- Uterine Fibroids With Menorrhagia

## Interventions

- **DRUG:** CMS-D002 Capsules 10 mg
- **DRUG:** CMS-D002 Capsules 25 mg
- **DRUG:** CMS-D002 Capsules 50 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07402369
- **Lead sponsor:** Shenzhen Kangzhe Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-19
- **Primary completion:** 2027-01-03
- **Final completion:** 2027-12-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07402369

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07402369, "Phase II Study of CMS-D002 Capsule for Uterine Fibroids With Menorrhagia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07402369. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*